Copy number aberrations (CNAs) are frequently found in cancer genomes and believed to be tumorigenic. Unfortunately, CNAs often occur in wide regions of the cancer genome that harbor a large number of genes, making it a challenge to identify the candidate cancer drivers. Further, subtypes of cancer may be characterized with distinct CNA patterns and hence have different drivers.
I. INTRODUCTION
Cancers are initiated and driven by aberrant genetic events (a.k.a. hits), such as copy number aberrations (CNAs), called the drivers of cancer. Further, quite a few cancers, such as breast cancer [1] , glioblastoma [2] and medulloblastoma [3] , are believed to contain subtypes, each with distinct molecular profiles and clinical outcomes. Different subtypes may have arisen because of different mechanisms, such as the hits on different pathways and/or different cells-of-origin [4] within the same tissue/organ. Stratifying the patients into appropriate subtypes is the key to uncover the drivers of these mechanisms.
There is a plethora of literature dedicated to the development of supervised [5] , semi-supervised [6] or unsupervised [7] approaches for the discovery of classes within a cancer dataset. However, there are major differences between class discovery and cancer subtyping:
• The levels of data for analysis are different. In class discovery, typically one level of data (e.g., gene expression data, copy numbers/sequencing data or clinical data) is used, whereas in subtyping, a combination of these datasets may need to be considered. The reason is that the establishment of a cancer subtype requires evidences at various levels of behaviors. • The objectives of features selection are different. While feature selection algorithms such as SVM-RFE [8] attempt to find a subset of genes with maximal predictive power; to ensure the functional interpretability, the feature selection criteria in subtyping also include the subtype-specificity of selected genes (i.e., gene signature). On the other hand, the subtypes and corresponding signature thus identified may shed light on the subtype-specific cancerous process. Also, genetic aberrations enriched in a particular subtype may be related to, or even have causing roles in these processes. Particularly, one type of genetic events, CNA, is widely found in the cancer genomes [9] and they occur at the DNA level, which is on the upper stream of gene expressions as dictated by the central dogma of biology. CNAs are also found to be positively correlated with the raw expressions of affected genes [3] . In some cancer, such as medulloblastoma, the CNA patterns are also found to be subtype-dependent [10] .
However, given the large number of CNA-affected genes that often occur within a cancer genome, it is not practical to assume that all of them are tumorigenic. Instead, most of the CNAs may just cause mechanic responses in the affected genes' expressions, but otherwise not involve in the cancerous process. Apart from these, a small proportion of CNAs may have involved in the initiating, driving or sustaining of the cancerous process, that gives rise to the subtype-specific signature. Fig. 1 summarizes the machinery of CNA-induced cancerous process inside a subtype. From the figure, the gene signature may reflect underlying processes characterizing individual subtypes. Therefore, performing cancer subtyping by signature selection may be closer to the definition of 'subtype' and help unveil the common mechanism within a subtype. Towards this end, we propose an integrative approach to perform subtyping based on gene expressions and driveridentification based on CNA measurements (e.g., SNP arrays). This paper is organized as below. Sections II and III discuss the gene-signature based iterative subtyping approach and the PCA based driver identification, respectively. In Section IV, we apply the algorithm to datasets of a cancer, medulloblastoma, and compare our findings with other methods. Section V discusses the results of the algorithms.
II. THE SUBTYPING ALGORITHM
As described above, gene expression signature underpins the biological processes, and is usually enriched in known canonical pathways, and hence using it for subtyping may be more accurate than by geometric clustering. We therefore propose to integrate signature detection into the subtyping process. A general framework is proposed as below: 1. Given an expression dataset = { , | = 1.. , = 1.. } with samples and genes, select an initial set of genes, Φ, say the top 10% of genes with largest variances, to yield a reduced datasetˆ= { , | ∈ Φ}. 2. Perform clustering onˆ. 3. Determine the number (say, ) of clusters inˆ, and divide the samples into subgroups. 4. Detect the subtype-specific DEGs using the original dataset , i.e., signature , for each subtype ∈ {1, .., }. 5. Update Φ using the new gene set Φ = 1 ∪, .., ∪ . 6. Updateˆwith the new set of signature genes Φ. 7. Repeat Steps 2 to 6, till certain convergence criterion, (e.g. stability of the signature genes) is reached. To implement the above framework, there are a few issues to address:
• The existence of outliers. Most subtyping methods are extremely sensitive to outliers. These samples may be because of rare disease mechanisms, noisy measurements or mislabeling of samples, etc.
• The clustering metric. As compared with Euclidean distance in the linear space, principal component (PC) based and kernelized distance metric puts stronger emphasis on the localized information of a set of samples. This is particularly useful in unveiling the underlying topology of a dataset. • Determining the number of subtypes. This is an open challenge in unsupervised learning and cancer subtyping. For example, in medulloblastoma, recent works had estimated the number of subtypes at four [11] , five [3] and six [10] , and receive almost equal acceptance. This makes cross-study comparison difficult. • Gene signature detection. Detection of DEGs in the two-class or even multiple-class scenarios has been extensively explored [12] , [13] . However, there has not been much emphasis on the subtype-specificity of these measures. The following subsections discuss the solutions to these problems.
A. Outlier (Marginal Sample) Detection
In this paper we use methods that are generally used in outlier detections to detect marginal samples. It is assumed that marginal samples lie in sparse regions, i.e., a sample is said to be marginal if it is on average much further away from its neighbors than would be core samples. We adopt a heuristic proximity-based approach, i.e., the -NN based algorithm [14] . Let be the average distance of all the samples to their centroid, i.e.,
to be marginal if the average distance of this sample to its closest neighbors, called score of marginality (SMar), is greater than , where is a user-specified scaling factor. Consequently, the detected marginal samples are retained for testing and the remaining samples (i.e., core samples) are used for training.
B. Clustering and Determining the Number of Clusters
There are many unsupervised techniques that can be used for clustering, such as the heuristic-based -means [15] , the topology-based self-organizing map [16] , non-negative matrix factorization [7] , etc. A major problem in cancer subtyping is that in different subtypes, different pathways or processes might have been turned on or off and the resulting DEGs may be under very different degrees of regulation. As a result, in the gene expression space, samples of certain subtypes may tightly disperse in a constrained space, whereas samples of other subtypes may loosely occupy another space. That is, different subtypes may have different densities of samples in the gene expression space. Algorithms such as hierarchical clustering (HC) [17] tend to cluster the densely populated space before joining the sparsely populated space. As a result, class boundaries obscure. And cluster boundary determination by a uniform threshold on the joining heights of dendrograms could be error-prone [18] . The situation worsens if the numbers of samples in the subtypes are highly imbalanced.
To tackle these, we employ two strategies:
• Performing clustering in the topological space. Such techniques use the inter-sample distances as a new metric and penalize long distances by subjecting them to a (e.g. Gaussian) kernel. The resulting datasets represent localized information of individual samples. • Using a one-cluster-at-a-time method. The first cluster is detected and removed before the remaining data are used for further detection. The algorithm terminates if no further cluster can be found. Specifically, given a datasetˆ= [ 1 , .., ] , the following steps are taken (cf. [19] ): a. Construct an affinity matrix such that
with largest eigenvalues. Empirically, can be determined by the maximum number such that the ratio between the th eigenvalue and the first one remains above certain threshold (0.05, say). d. Use the rows of to perform clustering and construct a dendrogram. e. Starting from the root of the dendrogram, check if a split is necessary by the gap-statistic [20] . If the resulting split results in significant drop of within-cluster variance, the dendrogram should be split into two trees. f. Proceed the check recursively in the resulting trees in a breadth-first manner. If a resulting tree contains no significant splittable clusters or if the tree contains only a few samples, the tree itself becomes a cluster and is removed. g. Carry on the above step till all resulting trees are examined. h. Perform gene-signature detection for the resulting clusters. And conduct a pair-wise comparison on the gene signatures of all clusters. Merge two clusters if their gene signatures are similar.
C. Gene Signature Detection
A subtype signature is defined to be the set of genes whose expressions are either significantly up-or down-regulated in a subtype, as compared with those of all other subtypes, which may also include the normal samples. To identify the subtype signatures, a three step algorithm is developed: (i) detection of differentially expressed genes (DEGs), (ii) detection of subtype-specific DEGs, or subtype signature, and (iii) ranking of genes within a subtype signature.
To detect the DEGs, given expressions = [ 1, , .., , ] for gene and the subtyping result, an ANOVA is performed to test: 0 : 1 = .. = , where is the mean of the within-subtype mean of gene for subtype . To account for the large number of comparisons, we use the family-wise error rate (FWER) as corrected by the Holm-Bonferroni [21] method to select the top DEGs.
In a multiclass setting, subtype-specific DEGs can be detected via post-hoc analysis. For each of the DEGs detected in the ANOVA, Tukey's honest significance test (TukeyHSD) [22] is followed to conduct a pair-wise comparison of its expression in one subtype with that in another. A DEG is said to be specific to a subtype, if the TukeyHSD signs of it in that subtype's comparisons with all other subtypes are identical, i.e., all positive or all negative, and the corresponding adjusted -values are all significant. It is worth noting that no restrictions are imposed on other adjusted -values in the TukeyHSD test, which allows for slight inter-subtype variations in the non-specific subtypes.
Finally, a ranking of each subtype's specific genes is needed to provide an order of functional relevance for these genes. To this end, for each subtype, a comparison for each of the detected signature genes in this subtype, against all other samples as a group, is performed. The subtype signature genes are ordered according to their corresponding -values. LIMMA [13] with BH [23] false discovery rate (FDR) control is applied in this step. At the end of these steps, we obtain a set of ranked signature genes for subtype .
III. THE SUBTYPE-SPECIFIC DRIVER IDENTIFICATION ALGORITHM
According to Fig. 1 , even within a subtype, there could be different driving events. Here, we focus on the dominant subtype-specific events, i.e., CNAs. CNAs often occur on a broad region in the cancer genome and presumably harbor far more genes than necessary to trigger cancer. As a result of the efficient responses from CNAs, most of which may be mechanic but otherwise non-cancerous, the search for candidate CNAs that might be responsible for the cancerous process becomes challenging (cf. Fig. 1 ). Nevertheless, the subtype-specific DEGs, i.e., gene signature, offer a retrospective clue for subtype-specific driver identification.
A CNA-affected gene can activate the cancerous process through its CNA-induced aberrant expressions. Therefore, its expression may likely be correlated with the signature genes, which are believed to be the consequences of subtypespecific processes.
To identify the drivers, for a subtype and its signature (| | ≜ ), and candidate CNA genes, an -bymatrix of pair-wise Pearson correlation coefficients between the signature genes and the expressions of the CNA genes is computed, using the within-subtype samples only. We may assume that a row-wise zero-meaned operation has been applied to . A PCA approach can next be applied to determine the correlation of each CNA with the set , as follows: a. Perform an SVD: = Σ , and then project onto the first principle vector 1 of , to give 1 = 1 . The individual entry of 1 represents the overall correlation of each CNA gene with the set of signature genes. b. For a candidate CNA gene ∈ {1, .., }, the more positive 1 is, the more gene is positively correlated with , and vice versa. Therefore, the values of 1 provide a ranking for the candidate CNA genes. c. The -values of 1 can be obtained by generating a random set of signature genes and repeating the above procedure to produce a null distribution for 1 . The candidate drivers can then be ranked by their -values. The set of candidate CNA genes can be obtained by finding the set of significantly recurrent CNAs in subtype via GISTIC [24] using the SNP arrays matching to the samples in .
IV. RESULTS AND DISCUSSION
To implement the proposed approach, we applied it to medulloblastoma (MB) datasets. MB is a pediatric brain tumor that usually affects children below the age of 15. The overall five-year survival rate for MB-affected children is poor (around 50% [25] ) and varies a lot from patient to patient, subject to different predisposition conditions. Integrative genomic studies [3] , [10] in recent years have attempted to classify MB patients into various numbers of subtypes, two of which are well-accepted, namely, the Wntand Shh-pathway associated subtypes, respectively. For the remaining non-Wnt/non-Shh patients, there are still debates on whether to characterize them as a single or multiple subtypes.
Two publicly available medulloblastoma datasets were used. The first dataset consists of 76 primary MB samples by Cho et al. [10] . The second dataset consists of 62 primary MB samples from Kool et al. [3] (GEO accession number: GSE10327). For convenience, the two datasets are referred to as 1 and 2 , respectively. Note that 2 uses a newer gene expression array and contains more probesets than 1 . For simplicity, only probesets common to both 1 and 2 are used.
A. Subtyping Result
The proposed score of marginality (SMar) in Section II was first applied to both datasets. Fig. 4A-B shows the result of this step. Ultimately, 75 and 60 core samples are identified in 1 and 2 , respectively. These core samples are separately trained with the proposed subtyping algorithm. The application to 1 terminates with three clusters as in Fig. 4C . When applying to 2 , the algorithm makes three splits before it finds that the third splits (the * mark in Fig. 4D ) results in child trees that are almost identical in gene signatures (85.67% overlap, compared with only 2.42% overlap between Subtype A and C). Therefore, a decision was made to merge the two clusters into one subtype. Finally, the algorithm puts the estimates of numbers of subtypes to be three in both datasets. For convenience, the three subtypes of 1 are denoted as A, B and C, respectively; and those of 2 are denoted as a, b and c, respectively. The signatures of individual subtypes in both datasets and their pairwise overlaps are shown in Table I . Obviously, Subtype A in 1 corresponds to Subtype a in 2 , and so forth. Fig. 3 shows some top-ranked signature genes for individual subtypes. It is not hard to see that Subtype A To conduct a cross-dataset validation, we used the gene signatures and trained cluster membership in 1 to predict the cluster membership in 2 , and vice versa. Table II lists the result. It can be seen that all but one sample in 1 are predicted with class labels that correctly match their trained labels. The outlier in 1 is predicted to be Subtype B, while the two outliers in 2 are both predicted to be Subtype C.
B. Driver Identification Result
Copy number measurements via SNP arrays of 1 were processed and submitted to GISTIC (via genepattern.broadinstitute.org) for detection of recurrent CNAs within each subtype. The results of this pre-selection step are listed in Table III . As described in Section III, within-subtype correlations between the pre-selected CNAs and the gene signature were then conducted and the PCA-based ranking method was applied. The projected vector 1 and the null distributions are shown in Fig. 4 . Note that in Subtype A, the CNA genes tend to be negatively correlated with the gene signature, whereas those in Subtypes B&C tend to be positively correlated. This is perhaps because of the predominant deletion patterns of Chr6 in Subtype A. Table IV shows the top-ranked ( -value < 0.01) candidate drivers in each subtype. Of note, all three subtypes contain some genes that seem to suggest the underlying pathways that characterize the subtypes. For example, Subtype A candidate drivers include MAP3K7, which has inhibiting roles in the Wnt-pathway [26] . Its deletion might cause the difficulty to inactivate Wnt-pathway and results in a persistently activating Wnt-pathway. Further, TULP4 is recently identified as a candidate suppressor gene in the Wntassociating subtype [27] . The top candidate driver in Subtype B, PTCH1, is a key gene in the Shh-pathway. Its deletion may result in the inability to inhibit Smoothened, and activate Shh permanently. Indeed, mutations in PTCH1 have been one of the top targets in recent literature attempting to find predisposition loci for MB [28] . Perhaps of most interest is the Wnt-associating genes, such as FZD1, PPP3CB and NLK, that are found in Subtype C. As compared with Wntand Shh-subtypes, the gene signature of this subgroup of MB does not seem to be significantly enriched with any canonical pathways. The candidate drivers that significantly correlate with the signature genes here seem to suggest that some Wnt-pathway activities are involved in Subtype C; although the exact roles of Wnt have yet to be clarified, as both NLK and FZD1 are amplified but the former has inhibiting while the latter has promoting roles.
V. CONCLUSION
In this work, a two-step algorithmic framework is developed to perform gene-signature based cancer subtyping and to identify subtype-specific CNAs drivers. The algorithm was applied to datasets of medulloblastoma, producing dataset-invariant subtyping results. The driver identification results were found to be enriched with cancer-driving pathways. This study has contributions in several aspects.
First, a subtyping technique depending on the signaturebased clustering addresses quite a few issues in unsupervised learning of cancer datasets. Particularly, the emphasis on subtype-specificity for gene signature detection allows for functional interpretation of the cancerous process or pathways underlying each subtype.
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